ME3183-3 Enrolling

Moderate to Severe Plaque Psoriasis Research (24 Weeks)

Treatment: Oral Age: 18 Years

Adults aged 18 to 75 years (inclusive) with a diagnosis of plaque psoriasis for 24 weeks or more, may qualify for this study. Qualified participants must also have moderate to severe disease with psoriatic plaques covering 10% or more body surface area. Individuals with a diagnosis of non-plaque psoriasis or drug-induced psoriasis, are not qualified for this study.

Participants will receive investigational oral medication (active study drug) or placebo. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 24 weeks and involve about 9 visits to the study centre.

The following information is from

Last Update Posted: November 27, 2022

Official Title

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Efficacy and Safety of ME3183 Administered Orally in Subjects With Moderate to Severe Plaque Psoriasis ID



Meiji Pharma USA Inc.

Study Description

  • Brief Summary:

    The purpose of this study is to assess the efficacy and safety of ME3183 administered orally for moderate to severe plaque psoriasis in adults.

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: ME3183
    Drug: ME3183
    Drug: ME3183
    Drug: ME3183
    Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 75 Years (Adult)

  • Sexes Eligible for Study:


Inclusion Criteria:

Male and female, ages 18 to 75 years
Participant with stable moderate to severe chronic plaque psoriasis of at least 24 weeks duration.

Exclusion Criteria:

Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease.
Active or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at Screening.
Hepatitis B surface antigen positive at Screening.
History of HIV or Positive for the HIV antibodies at Screening.
History of allergy to any component of the study treatment.
Active tuberculosis (TB) or a history of incompletely treated TB.
Active infection (bacteria, viral, fungal, etc.) requiring treatment with systemic antibiotics within 4 weeks of Screening.
Malignancy or history of malignancy except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence.
Pregnant or breast feeding
Received ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, risankizumab, tildrakizumab, or briakinumab within 24 weeks of first administration of study treatment.
Received TNF-α inhibitor(s)/blocker(s) within 8 weeks of first administration of study treatment.
Received rituximab within 24 weeks of first administration of study treatment.
Received phototherapy or any systemic medications/treatments within 4 weeks of the first administration of study treatment.

Other protocol defined inclusion/exclusion criteria could apply

Terms and Conditions –
Purpose of Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed to provide patients, family members, and members of the public current information about clinical research studies.

Participating Locations

Participating Experts

Dr. Kim Alexander Papp


Dr. Maxwell Sauder


Dr. Anatoli Freiman


Dr. Benjamin Barankin


Dr. Mani Raman


Dr. Michael R. Robern


Dr. Mark Lomaga


Dr. Charles Lynde


Dr. Wei Jing Loo


Dr. Melinda Gooderham


You May Also Be Interested In

Similar Trials

No Similar Trials Found

Learn More About


Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials